Antibacterial Agents TRIZ Cases

Hybrid vaccine formulations merge protein conjugates with polysaccharide antigens to extend antibody duration and broaden serotype coverage.

Strain CNCM I-4720 delivers universal protection against multiple serogroups, resolving the limited cross-immunity of current vaccines.

A phenol derivative composition inhibits STAT3 signaling to treat inflammatory diseases.

Gastric floating tablets increase chlorogenic acid bioavailability, enabling effective LAG-3 inhibition for treating tumors and sepsis.

Rv2386c antigens target latent TB reactivation, resolving BCG vaccine limitations by addressing dormant bacterial stages.

Novel albicidin derivatives with modified rings demonstrate potent antimicrobial activity against bacterial strains.

Trehalose and sucrose protect extracellular vesicles during freeze-drying, maintaining stability while enabling easier handling of dried therapeutic forms.

Pyrimidone compounds inhibit Lp-PLA2 activity, reducing lyso-PC levels and improving blood-brain barrier permeability in atherosclerosis.

A minocycline composition combined with oxidized regenerated cellulose degradation products delivers broad-spectrum antimicrobial activity through synergistic interaction.

Hydrazide chemistry enables rapid polysaccharide-protein conjugation, reducing lengthy purification steps and unreacted material.

Modified angiopoietin activates Tie2 receptors to protect the blood-brain barrier, reducing mortality and neurological impairments caused by cerebral malaria.

Anti-IRC85 monoclonal antibody binds to IRC85 receptors on monocytic cells to remove infected bacteria, preventing tuberculosis and enteritis.

Selective antagonists targeting DP1, FP, EP1, and EP4 receptors reduce gastrointestinal toxicity while maintaining broad anti-inflammatory coverage.

A gingerol derivative binds to the LasR protein to disrupt quorum sensing and inhibit biofilm formation in Pseudomonas aeruginosa.

High-concentration antibiotic combinations eradicate bacteria at the infection site while avoiding systemic toxicity.

Combined aqueous immunogenic composition with conjugated saccharides and polypeptide antigens.

Pyrimidinone immunomodulators overcome pathogen resistance by enhancing host immune functions like mitogenicity to treat hepatitis C.

Low-water phospholipid depots with antibiotics prevent heat degradation during sterilization while maintaining stability.

Adjusting pH below 3.5 stabilizes the iodine complex, extending shelf life to 24 months while maintaining efficacy against spore-forming bacteria.

Structural modifications enable oral administration of carbapenems, resolving the trade-off between short half-life and intravenous route requirements.

Topical human milk oligosaccharides inhibit Cutibacterium acnes growth to prepare skin for healthy strain transplantation.

A molecular assembly system generates chimeric antigen receptors by combining diverse antigen binding domains with standardized hinge and signaling regions.

Modifying oxazolidinone substituents overcomes limited effectiveness and resistance development in current antibacterial treatments.

Synergizes morpholino compounds with cetylpyridinium salts to overcome low antibacterial activity against Staphylococcus biofilms.

E. coli produces inclusion bodies containing fusion peptides from Avibacterium paragallinarum serotypes A and C.

Novel rifamycin congeners inhibit growth of resistant bacteria by targeting specific RNA polymerase mutations.

Oral Lactobacillus casei agent treats chlamydia infection without side effects from prolonged antibacterial use, improving fertility rates.

Tetrahydropyrido-pyridine compounds inhibit C5a receptor activation, reducing inflammation and slowing age-related macular degeneration progression.

Replacing monoclonal antibodies with a small molecule inhibitor reduces immunogenicity and production costs while enhancing tissue permeability.

Modified kaempferol compounds constrain RSK signaling to stop tumor growth and block pathogen endosomal maturation.

Conjugate vaccine formulations link pneumococcal polysaccharides to protein carriers.

Formula I compounds block bacterial efflux pumps, preventing antibiotic expulsion and lowering minimum inhibitory concentration.

Chimeric OspA antigens combine conserved sequences from multiple Borrelia species to overcome antigenic heterogeneity and provide broad-spectrum protection.

Lactoferrin binds iron to inhibit pathogenic bacteria, preventing menstrual flora disturbance and supporting Lactobacillus dominance.

Buccal EGCG tablets bypass poor oral bioavailability by delivering high local concentrations that rapidly inactivate respiratory viruses.

Monoclonal antibodies bind to Clostridium difficile toxin B to neutralize cytotoxic effects and prevent infection relapse.

Specific heterobicyclic structures target the IGF-1R ATP-binding site, improving selectivity and potency while reducing toxicity.

Ecteinamycin disrupts ion transport and membrane potential to treat resistant bacterial infections.

Bacteriocins from Lactobacillus pentosus target E. coli without disrupting beneficial flora, resolving antibiotic resistance and side effect trade-offs.

Lactobacillus paracasei MG4272 suppresses pathogens while preserving vaginal flora balance, avoiding antibiotic resistance.

Humanized monoclonal antibodies target CCR4 receptors on tumor cells to induce selective killing via ADCC and CDC mechanisms.

Conjugating hydrophilic and hydrophobic materials to siRNA via a double-helical oligo RNA structure improves delivery efficiency while reducing immunogenicity.

Segmented DNA analysis of specific SNPs and HLA alleles targets high-risk patient populations, reducing recurrence rates while managing diagnostic complexity.

Removing bacterial cell walls creates protoplast-derived microvesicles that deliver drugs without endotoxin-induced inflammation.

An aminothiazole derivative inhibits bacterial elongation factor EF-Tu to disrupt protein synthesis.

Modifying polymyxin charge density reduces nephrotoxicity while maintaining effectiveness against multiresistant Gram-negative bacterial infections.

Zinc-α2-glycoprotein polypeptide mobilizes lipids to resolve hyperglycemia and obesity while increasing skeletal muscle mass.

Combining antibodies against alpha toxin, ClfA, and leukotoxins resolves the trade-off between treatment simplicity and broad strain coverage.